Pharmacologic reduction of E-selectin expression by approximately 60 % (using the clinically approved proteasome inhibitor bortezomib) is in case of these tumor cell lines sufficient to impair endothelial adhesion in vitro and spontaneous lung metastasis in vivo. The gene discussed is SELE; the disease is neoplasm.